Skip to main content
. 2020 Nov 30;18(4):2088. doi: 10.18549/PharmPract.2020.4.2088

Table 5. Session impact on cannabis product use.

Characteristic; n (%) Current Users (n=77) Naïve or Past Users (n=102)
Overall cannabis use
More use 26 (33.8) N/A
No change 18 (23.3) N/A
Less use 29 (37.7) N/A
THC use
Use a high THC product (>15%) 12 (15.6) 0 (0)
Use a medium THC product (6-14%) 21 (27.3) 5 (4.9)
Use a low THC product (<6%) 26 (33.8) 58 (56.9)
No change 17 (22.1) N/A
Not interested in using cannabis 0 (0) 6 (5)
Uncertain 0 (0) 33 (32.4)
CBD use
Use a high CBD product (>15%) 42 (54.5) 34 (33.3)
Use a medium CBD product (6-14%) 14 (18.2) 11 (10.8)
Use a low CBD product (<6%) 4 (5.2) 18 (17.6)
No change 13 (16.9) N/A
Not interested in using cannabis 0 (0) 4 (3.9)
Uncertain 0 (0) 35 (34.3)

THC – Tetrahydrocannabinol, CBD – Cannabidiol